Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Osteosarcoma 1Hodgkin Disease 1Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Cyclophosphamide 115fludarabine phosphate 67Mycophenolic Acid 62Etoposide 61Peripheral Blood Stem Cell Transplantation 58Tacrolimus 55Melphalan 48Filgrastim 48Busulfan 48Whole-Body Irradiation 47Doxorubicin 46Radiotherapy 42fludarabine 38Cyclosporine 38Brentuximab Vedotin 38Vinblastine 35Granulocyte Colony-Stimulating Factor 35Antilymphocyte Serum 30Methotrexate 29Dacarbazine 29Gemcitabine 28Rituximab 26Nivolumab 25Prednisone 24Bleomycin 24Vincristine 22pembrolizumab 21Carmustine 21Cytarabine 20thymoglobulin 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hodgkin Disease × indolepropanol phosphate × Clear all
NCT00381940 2021-03-24

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 14 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡